Corticosteroid treatment for prevention of prematurity complications

被引：5

作者：

Celik C. ^{[1
]}

Acar A. ^{[1
]}

Cicek N. ^{[1
]}

Koc H. ^{[1
]}

Ak D. ^{[1
]}

Akyurek C. ^{[1
]}

机构：

[1] Faculty of Medicine, Department of Obstetrics, Selcuk University, Akyokus/Konya

来源：

Archives of Gynecology and Obstetrics | 2002年 / 267卷 / 2期

关键词：

Corticosteroid treatment; Prematurity;

D O I：

10.1007/s00404-001-0271-6

中图分类号：

学科分类号：

摘要：

Objective: To investigate of efficiency to corticosteroid treatment for prevention of respiratory distress syndrome and other prematurity complications. Materials and Methods: One thousand and six babies born at 26-36th gestational age were investigated for following parameters; the development of respiratory distress syndrome, necessity of surfactant therapy, mean duration of daily ventillatory support, rates of Grade III or IV intraventricular hemorrhage, and periventricular leukomalacia, necrotizing enterocolitis, proven neonatal sepsis and neonatal death. Antenatal steroids were administered in the form of two 12-mg intramuscular doses of betamethasone 12 h apart as a total 24 mg in the 24 h and repeat courses of two 12 mg of betamethasone every 7 days after the first dose of the last course if undelivered. Babies were divided into 4 groups based on betamethasone treatment: The first group or control group didn't received treatment; the second group received treatment and delivered within 12 h after first injection; the third group delivered 12-24 h after first injection; and fourth group delivered at least 24 h after first injection. The patients ongoing pregnancy at least 1 week were divided into two groups as a single dose and multiple courses in once a week. Results: Significant difference for development of respiratory distress syndrome between fourth group and others was found (p=0.029). There were significant difference for respiratory distress syndrome rate in hypertansive and premature rupture of membranes groups between fourth group and control group (p=0.002, p=0.041). There weren't significant difference for RDS between repeat doses and single dose groups (p>0.05). Conclusion: Single dose corticosteroid is an effective treatment for the development of RDS and the prevention of other prematurity complications.

引用

页码：90 / 94

页数：4

共 26 条

[1]

Anyaegbunam W.I., Adetona A.B., Use of antenatal corticosteroids for fetal maturation in preterm infants, Am Fam Physician, 56, pp. 1093-1097, (1997)

[2]

Ballard P.L., Ballard R.A., Scientific basis and therapeutic regimens for use of antenatal glucocorticoids, Am J Obstet Gynecol, 173, pp. 254-262, (1995)

[3]

Bunt J.E., Carnielli V.P., Darcos Wattimena J.L., Hop W.C., Sauer P.J., Zimmermann L.J., The effect in premature infants of prenatal corticosteroids on endogenous surfactant synthesis as measured with stable isotopes, Am J Respir Crit Care Med, 162, pp. 844-849, (2000)

[4]

Crowley P., Antenatal corticosteroids therapy: A meta-analysis of the randomized trials, 1972-1994, Am J Obstet Gynecol, 173, pp. 322-335, (1995)

[5]

Dessens A.B., Haas H.S., Koppe J.G., Twenty-year follow-up of antenatal corticosteroid treatment, Pediatrics, 105, (2000)

[6]

Elimian A., Verma U., Visintainer P., Tejani N., Effectiveness of multidose antenatal steroids, Obstet Gynecol, 95, pp. 34-36, (2000)

[7]

Golden W.E., Hopkins R.H., Sanchez N.P., Antenatal corticosteroids for the prevention of neonatal respiratory distress in a predominantly rural state medicaid population, Obstet Gynecol, 92, pp. 837-841, (1998)

[8]

Hohlagschwandtner M., Husslein P., Klebermass K., Weninger M., Nardi A., Langer M., Perinatal mortality and morbidity. Comparison between maternal transport, neonatal transport and inpatient antenatal treatment, Arch Gynecol Obstet, 265, pp. 113-118, (2001)

[9]

Jones S.C., Brost B.C., Brehm W.T., Should intravenous tocolysis be considered beyond 34 weeks' gestation?, Am J Obstet Gynecol, 183, pp. 356-360, (2000)

[10]

Kay H.H., Bird I.M., Coe C.L., Dudley D.J., Antenatal steroid treatment and adverse fetal effects: What is the evidence?, J Soc Gynecol Invest, 7, pp. 269-278, (2000)

← 1 2 3 →